Featured news in The Life Sciences Report



DURECT Corp. (DRRX:NASDAQ)
DURECT Announces Closing of Public Offering of Common Stock (4/29/2016)

view
 


RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB)
RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price (4/29/2016)

view
 


DURECT Corp. (DRRX:NASDAQ)
DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call (4/28/2016)

view
 


Celgene Corp. (CELG:NASDAQ)
Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View (4/29/2016)

view
 

Celgene Corp. (CELG:NASDAQ)
Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook (4/28/2016)

view
 


MiMedx Group Inc. (MDXG:NASDAQ)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference (4/28/2016)

view
 


Caladrius Biosciences Inc. (CLBS:NASDAQ)
Caladrius Biosciences to Host 2016 First Quarter Financial Results Conference Call on May 5 at 5:00 pm Eastern Time (4/28/2016)

view
 


Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
StockNewsNow.com Publishes Q3 2015 Review SNNLive Video Interview With Immune Pharmaceuticals, Inc. (11/2/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid (11/9/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Provide Corporate Update on November 12, 2015 (11/5/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces Third Quarter 2015 Corporate Update, Financial Results and Conference Call Details (11/12/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology (12/28/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces Enrollment of the First Patient into the Phase 2 Clinical Trial with Bertilimumab in Ulcerative Colitis (11/17/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development (12/7/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody (12/14/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology (1/4/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Expands Leadership Team (11/19/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals CEO Updates Shareholders On Company Progress (12/9/2015)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan (1/12/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals to Present at 18th Annual BIO CEO & Investors Conference (2/8/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues (2/24/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals and The International Pemphigus & Pemphigoid Foundation (IPPF) Celebrate Rare Disease Day (2/29/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology (3/22/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Names John Neczesny to its Board of Directors (2/3/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors (2/10/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors (2/25/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting (3/17/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results (3/30/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age (4/19/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report (4/28/2016)

view
 

Immune Pharmaceuticals Inc. (IMNP:NASDAQ)
IMMUNE PHARMS INC reaches new 52-Week Low (4/22/2016)

view
 


Relmada Therapeutics Inc. (RLMD:NASDAQ)
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference (4/28/2016)

view
 


Celgene Corp. (CELG:NASDAQ)
Will Vertex (VRTX) Stock Decline on 1Q Earnings Miss? (4/28/2016)

view
 

Celgene Corp. (CELG:NASDAQ)
Celgene (CELG) Beats on Q1 Earnings, Misses on Revenues (4/28/2016)

view
 

Celgene Corp. (CELG:NASDAQ)
AbbVie (ABBV) Beats on 1Q Earnings, Lowers View on Deal (4/28/2016)

view
 


Sunesis Pharmaceuticals Inc. (SNSS:NASDAQ)
Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights (4/28/2016)

view